(Q57268157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

Gulnara Patrícia Borja-Cabrera

18 January 2020

main subject

visceral leishmaniasis

1 reference

1 reference

Quillaja saponaria

1 reference

based on heuristic

inferred from title

author

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

Luzineide Wanderley Tinoco

18 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

José Paz Parente

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

Clarisa Beatriz Palatnik-de-Sousa

18 January 2020

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Oliveira-Freitas E

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Casas CP

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Santos FN

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Nico D

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Souza LO

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

da Silva BP

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Palatnik M

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

2 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

3909-3920

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Triterpenoid saponins containing an acetylated branched D-fucosyl residue from Quillaja saponaria Molina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

QS-21 structure/function studies: effect of acylation on adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Covalent chemical events in immune induction: fundamental and therapeutic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Isomerization and formulation stability of the vaccine adjuvant QS-21

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Multiple-stage tandem mass spectrometry for structural characterization of saponins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

Structure-function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

The effects of protein stabilizers on aggregation induced by multiple-stresses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.02.034

10.1016/J.VACCINE.2006.02.034

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16556475%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference